Literature DB >> 14522969

Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides.

Jonathan Villemaire1, Isabelle Dion, Sherif Abou Elela, Benoit Chabot.   

Abstract

Alternative pre-messenger RNA splicing is a major contributor to proteomic diversity in higher eukaryotes and represents a key step in the control of protein function in a large variety of biological systems. As a means of artificially altering splice site choice, we have investigated the impact of positioning proteins in the vicinity of 5' splice sites. We find that a recombinant GST-MS2 protein interferes with 5' splice site use, most efficiently when it binds upstream of that site. To broaden the use of proteins as steric inhibitors of splicing, we have tested the activity of antisense oligonucleotides carrying binding sites for the heterogeneous nuclear ribonucleoprotein A1/A2 proteins. In a HeLa cell extract, tailed oligonucleotides complementary to exonic sequences elicit strong shifts in 5' splice site selection. In four different human cell lines, an interfering oligonucleotide carrying A1/A2 binding sites also shifted the alternative splicing of the Bcl-x pre-mRNA more efficiently than oligonucleotides acting through duplex formation only. The use of protein-binding oligonucleotides that interfere with U1 small nuclear ribonucleoprotein binding therefore represents a novel and powerful approach to control splice site selection in cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14522969     DOI: 10.1074/jbc.M308897200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  A G-rich element forms a G-quadruplex and regulates BACE1 mRNA alternative splicing.

Authors:  Jean-François Fisette; Daniel R Montagna; Mihaela-Rita Mihailescu; Michael S Wolfe
Journal:  J Neurochem       Date:  2012-03-13       Impact factor: 5.372

2.  An artificial riboswitch for controlling pre-mRNA splicing.

Authors:  Dong-Suk Kim; Veronica Gusti; Sailesh G Pillai; Rajesh K Gaur
Journal:  RNA       Date:  2005-11       Impact factor: 4.942

3.  Antisense therapeutics: New ways to nudge splicing.

Authors:  Ian Eperon
Journal:  Nat Chem Biol       Date:  2012-05-17       Impact factor: 15.040

Review 4.  Targeting RNA-splicing for SMA treatment.

Authors:  Jianhua Zhou; Xuexiu Zheng; Haihong Shen
Journal:  Mol Cells       Date:  2012-02-28       Impact factor: 5.034

5.  Alternative splicing of SYK regulates mitosis and cell survival.

Authors:  Panagiotis Prinos; Daniel Garneau; Jean-François Lucier; Daniel Gendron; Sonia Couture; Marianne Boivin; Jean-Philippe Brosseau; Elvy Lapointe; Philippe Thibault; Mathieu Durand; Karine Tremblay; Julien Gervais-Bird; Hanad Nwilati; Roscoe Klinck; Benoit Chabot; Jean-Pierre Perreault; Raymund J Wellinger; Sherif Abou Elela
Journal:  Nat Struct Mol Biol       Date:  2011-05-08       Impact factor: 15.369

6.  Bcl-x pre-mRNA splicing regulates brain injury after neonatal hypoxia-ischemia.

Authors:  Qingli Xiao; Andria L Ford; Jan Xu; Ping Yan; Kuang-Yung Lee; Ernesto Gonzales; Tim West; David M Holtzman; Jin-Moo Lee
Journal:  J Neurosci       Date:  2012-09-26       Impact factor: 6.167

Review 7.  Alternative splicing and disease.

Authors:  Jamal Tazi; Nadia Bakkour; Stefan Stamm
Journal:  Biochim Biophys Acta       Date:  2008-10-17

8.  Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.

Authors:  Aurélie Goyenvalle; Arran Babbs; Gert-Jan B van Ommen; Luis Garcia; Kay E Davies
Journal:  Mol Ther       Date:  2009-05-19       Impact factor: 11.454

9.  Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy.

Authors:  Travis D Baughan; Alexa Dickson; Erkan Y Osman; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2009-02-19       Impact factor: 6.150

Review 10.  Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies.

Authors:  Jianhua Zhou; Qingming Yu; Tie Zou
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.